TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33075332

Group type: EXPERIMENTAL
Intervention: Methylergonovine
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 33324593

Group type: EXPERIMENTAL
Intervention: Isoniazid exposure during tuberculosis preventive treatment (IPT)
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Multi-B vitamin therapy (containing 300 mg nicotinamide daily) and isoniazid cessation
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Measurement of niacin metabolites (1-methylnicotinamide and l-methyl-2-pyridone-5-carboxamide) in urine
Number of subjects: 985
Study: 36333751

Group type: EXPERIMENTAL
Intervention: Early stellate ganglion block (e-SGB)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Camouflaging action before anesthesia induction (Control)
Number of subjects: 228
Study: 34145993

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 μg/kg/min for 24 hours)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35612664

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 12 features extracted from preoperative contrast-enhanced CT imaging.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating significant pathological predictors and radiomics signatures.
Number of subjects: 204
Study: 33203462

Group type: EXPERIMENTAL
Intervention: Case management from hospital discharge up to 2 years thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case management
Number of subjects: 0
Study: 34885211

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 504

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Continuous DS
Number of subjects: 504
Study: 32259835

Group type: EXPERIMENTAL
Intervention: Intensive support intervention (resistance exercise training and individual dietary counseling)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate support intervention (resistance exercise training and nutrition course)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Individual dietitian consultations
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nutrition course
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Moderate support intervention
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intensive support intervention
Number of subjects: 82
Study: 35991268

Group type: EXPERIMENTAL
Intervention: RUSH process (Group-A, n=52)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group-B, n=48)
Number of subjects: 100
Study: 34349488

Group type: EXPERIMENTAL
Intervention: FAR + SOC
Number of subjects: 68

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 68
Study: 35460070

Group type: EXPERIMENTAL
Intervention: HPV-based screening (HPV Arm) at 48-month intervals
Number of subjects: 111

Group type: COMPARATOR
Intervention: Cytology (Cytology Arm) at 24-month intervals
Number of subjects: 111
Study: 33243239

Group type: EXPERIMENTAL
Intervention: Genetically predicted cortisol (based on 6 SNPs from CORNET)
Number of subjects: 12597

Group type: COMPARATOR
Intervention: Genetically predicted IHD, ischemic stroke, and T2DM
Number of subjects: 12597
Study: 35270384

Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education and Motor Control Exercises (PNE/MCE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Core Stability Training (CST)
Number of subjects: 37
Study: 33979354

Group type: EXPERIMENTAL
Intervention: Omentin A326T (rs2274907) SNP
Number of subjects: 1886

Group type: EXPERIMENTAL
Intervention: Circulating adiponectin concentrations
Number of subjects: 1886

Group type: COMPARATOR
Intervention: Adiponectin levels
Number of subjects: 1886
Study: 32396131

Group type: EXPERIMENTAL
Intervention: Trans Women Connected mobile app
Number of subjects: 16
Study: 34406254

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy applied at 50 Hz, 25 G intensity, 20 min/session
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Field (PEMF) therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham group (device turned off)
Number of subjects: 40
Study: 32278684

Group type: EXPERIMENTAL
Intervention: Marijuana users
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-marijuana users
Number of subjects: 51
Study: 35687846

Group type: EXPERIMENTAL
Intervention: Statistical parametric mapping (SPM) analysis of 1-dimensional (1D) force-time curves
Number of subjects: 32

Group type: COMPARATOR
Intervention: Zero-dimensional (0D) analysis of peak force
Number of subjects: 32
Study: 32929521

Group type: EXPERIMENTAL
Intervention: TMR+RFF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TMR+RFF with modified reconstruction
Number of subjects: 50

Group type: COMPARATOR
Intervention: pCRT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TMR+RFF and pCRT
Number of subjects: 50
Study: 32703200

Group type: EXPERIMENTAL
Intervention: CAPOXIRI plus bevacizumab (BEV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab (BEV)
Number of subjects: 100
Study: 35870942

Group type: EXPERIMENTAL
Intervention: Video‐feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 40
Study: 33999486

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4956

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4956
Study: 32792250

Group type: EXPERIMENTAL
Intervention: IIV by MNP administered by healthcare worker (HCW)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IIV by MNP self‐administered by study participants
Number of subjects: 100

Group type: COMPARATOR
Intervention: IIV by intramuscular (IM) injection administered by HCW
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo by MNP administered by HCW
Number of subjects: 100
Study: 35322156

Group type: EXPERIMENTAL
Intervention: Risk-score model for opioid overdose
Number of subjects: 1752380

Group type: COMPARATOR
Intervention: Control group (4 controls per case of overdose)
Number of subjects: 1752380
Study: 35851746

Group type: EXPERIMENTAL
Intervention: Mepilex Lite®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Band-Aid®
Number of subjects: 0
Study: 33870760

Group type: EXPERIMENTAL
Intervention: Topical skin adhesive (TSA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nylon sutures (NSs)
Number of subjects: 70
Study: 32386451

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) questionnaire
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model based on CAT scores and socio-demographic/work-related factors
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Another model including CAT breathlessness
Number of subjects: 1203
Study: 34292180

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg preoperatively + 40 mg/day postoperatively (80/40-mg group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day postoperatively (20-mg group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day postoperatively (40-mg group)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Procalcitonin, hs-CRP, highly sensitive cardiac troponin T, Gensini score
Number of subjects: 112
Study: 34239934

Group type: EXPERIMENTAL
Intervention: Aquatic environment rehabilitation (4 weeks, 5 times a week for 30 minutes)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Gym rehabilitation (4 weeks, 5 times a week for 30 minutes)
Number of subjects: 137
Study: 35453173

Group type: EXPERIMENTAL
Intervention: 60mg ketorolac
Number of subjects: 56

Group type: COMPARATOR
Intervention: 80mg triamcinolone acetonide
Number of subjects: 56
Study: 32804869

Group type: EXPERIMENTAL
Intervention: Iliac autograft (group I; n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral autograft (group II; n=30)
Number of subjects: 60
Study: 32415684

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selexipag 200 μg twice daily
Number of subjects: 0
Study: 32930620

Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant Enterobacteriaceae (CRE) infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbapenem-susceptible Enterobacteriaceae (CSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factors for CRE infection
Number of subjects: 0
Study: 35355656

Group type: EXPERIMENTAL
Intervention: Norepinephrine (6 μg/mL) infused at 60 mL/h
Number of subjects: 62

Group type: COMPARATOR
Intervention: Phenylephrine (75 μg/mL) infused at 60 mL/h
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Norepinephrine and Phenylephrine
Number of subjects: 62
Study: 34229451

Group type: EXPERIMENTAL
Intervention: Virtual Native Enhancement (VNE)
Number of subjects: 1348
Study: 32480319

Group type: EXPERIMENTAL
Intervention: Mobile application access (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No mobile application access (Control)
Number of subjects: 75
Study: 35254839

Group type: EXPERIMENTAL
Intervention: IV nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg/70 kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IV nicotine (0.2 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IV nicotine (0.1 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 34
Study: 33474960

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing combined with 3M Cavilon No-Sting Barrier Film
Number of subjects: 116
Study: 32275361

Group type: EXPERIMENTAL
Intervention: Tiaoshen acupuncture (acupuncture for regulating the spirit) applied in the observation group, including additional acupoints Baihui (GV 20), Shenting (GV 24), and Benshen (GB 13). Treatment given once a day, 6 times a week, for 3 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional acupuncture at lower limbs' acupoints (Zusanli (ST 36), Yanglingquan (GB 34), and Xuanzhong (GB 39)) applied in the control group. Treatment given once a day, 6 times a week, for 3 weeks.
Number of subjects: 60
Study: 33882347

Group type: EXPERIMENTAL
Intervention: Lesion network mapping with white matter hyperintensities (WMHs)
Number of subjects: 164
Study: 33019332

Group type: EXPERIMENTAL
Intervention: Normalization using root mean square (RMS) value
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normalization using mean value (DIMean)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normalization using maximum (DIPBI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: DI without normalization
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DIRMS
Number of subjects: 60
Study: 35877084

Group type: EXPERIMENTAL
Intervention: SOC plus docetaxel
Number of subjects: 690

Group type: COMPARATOR
Intervention: SOC
Number of subjects: 690
Study: 32524230

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fortified refined olive oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flax oil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Grapeseed oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (basal urine)
Number of subjects: 20
Study: 35347080

Group type: EXPERIMENTAL
Intervention: Automated continuous monitoring alert to initiate postextubation RT‐driven care
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard RT assessment tool
Number of subjects: 201
Study: 32412916

Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation with frequencies of 256 Hz in one ear and 260 Hz in the opposite ear (intervention group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acoustical stimulation at 256 Hz in both ears (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Binaural beats stimulation
Number of subjects: 40
Study: 33951339

Group type: EXPERIMENTAL
Intervention: 750 mg CBD twice daily with 200 mg caffeine on day 26
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo with 200 mg caffeine on day 1
Number of subjects: 16
Study: 35086348

Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 33236840

Group type: EXPERIMENTAL
Intervention: Periconceptional iron supplementation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no periconceptional iron supplementation)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Active placental malaria
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Child body iron stores
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 180
Study: 35633196

Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg/kg PO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetaminophen (30 mg/kg PO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (2.2 mg/kg PO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Oral placebo (C)
Number of subjects: 9
Study: 33819279

Group type: EXPERIMENTAL
Intervention: Snorkel mask
Number of subjects: 56

Group type: COMPARATOR
Intervention: FFP3 respirator mask
Number of subjects: 56

Group type: COMPARATOR
Intervention: FFP3 mask
Number of subjects: 56
Study: 32907603

Group type: EXPERIMENTAL
Intervention: Multicomponent implementation strategy including training and point-of-service tools (e.g., desktop chart with prompts for offering brief counseling)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Referral system available in arm 2
Number of subjects: 52
Study: 36416492

Group type: EXPERIMENTAL
Intervention: Psilocybin (0.143 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 16
Study: 33212068

Group type: EXPERIMENTAL
Intervention: CYD‐TDV (tetravalent dengue vaccine)
Number of subjects: 3967

Group type: EXPERIMENTAL
Intervention: Immunoassays (EUROIMMUN, Panbio, TELL ME FAST, SD BIOLINE, OnSite)
Number of subjects: 3967
Study: 32771996

Group type: EXPERIMENTAL
Intervention: Aspirin and ticagrelor for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel for 3 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patients without HPR continued on aspirin and clopidogrel
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bioprosthetic valves (BEV, SEV, other)
Number of subjects: 68
Study: 34797205

Group type: COMPARATOR
Intervention: Real GSM 900 MHz mobile phone exposure (pulse modulated at 217 Hz, mean power of 250 mW and 2 W peak, with a maximum specific absorption rate of 0.70 W/kg on 1 g tissue)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 21
Study: 34004172

Group type: EXPERIMENTAL
Intervention: HEBC intervention
Number of subjects: 1451
Study: 32729231

Group type: EXPERIMENTAL
Intervention: Collaborative education
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional didactic education
Number of subjects: 52
Study: 35843242

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care with salvage chemotherapy followed by autologous stem cell transplantation
Number of subjects: 0
Study: 32668475

Group type: EXPERIMENTAL
Intervention: hamstrings stretching plus whole-body vibration [S+WBV]
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: partial-body cryotherapy [Cryo]
Number of subjects: 11

Group type: COMPARATOR
Intervention: rest [Control]
Number of subjects: 11
Study: 32361928

Group type: EXPERIMENTAL
Intervention: Corticosteroid group (received periarticular infiltration of ropivacaine, epinephrine, and dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received periarticular infiltration of ropivacaine and epinephrine, without dexamethasone)
Number of subjects: 0
Study: 32487965

Group type: EXPERIMENTAL
Intervention: TIDieR checklist adherence
Number of subjects: 141

Group type: COMPARATOR
Intervention: TIDieR publication
Number of subjects: 141

Group type: COMPARATOR
Intervention: Trial registration
Number of subjects: 141
Study: 36286254

Group type: EXPERIMENTAL
Intervention: Haloperidol (2.5 mg 3 times daily plus 2.5 mg as needed, max 20 mg daily)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000
Study: 33929674

Group type: EXPERIMENTAL
Intervention: Normal Feedback (NF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Random Feedback (RF)
Number of subjects: 10
Study: 33402165

Group type: EXPERIMENTAL
Intervention: Increasing 30 min of total physical activity (PA)
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Increasing 30 min of moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Reallocating 30 min of inactive time to MVPA
Number of subjects: 1564
Study: 34311783

Group type: EXPERIMENTAL
Intervention: Respiratory facilitation technique performed for about three minutes, repeated for a total of 4/6 times in sequence, three times a day until spontaneous respiratory activity is achieved.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individualized postural care program including respiratory facilitation and autogenous drainage.
Number of subjects: 0
Study: 32096852

Group type: EXPERIMENTAL
Intervention: Abbreviated breast MRI
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Digital breast tomosynthesis (DBT)
Number of subjects: 1444
Study: 35422240

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (AAD)
Number of subjects: 144
Study: 34599031

Group type: EXPERIMENTAL
Intervention: Seviprotimut-L 40 mcg
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 34509591

Group type: EXPERIMENTAL
Intervention: DB+ALSA
Number of subjects: 20

Group type: COMPARATOR
Intervention: DB‐ACLR
Number of subjects: 20
Study: 33148211

Group type: EXPERIMENTAL
Intervention: Movement-to-music video program (8-week exercise intervention)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study: 35039305

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 33404659

Group type: EXPERIMENTAL
Intervention: Standard therapy plus belimumab
Number of subjects: 1684
Study: 34862877

Group type: EXPERIMENTAL
Intervention: Mirena
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dydrogesterone
Number of subjects: 60
Study: 34342477

Group type: EXPERIMENTAL
Intervention: Telephone counselling
Number of subjects: 208

Group type: COMPARATOR
Intervention: Routine surveillance by local health authority (Control)
Number of subjects: 208
Study: 32289380

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) and Prednisone (P) based regimen
Number of subjects: 8820
Study: 35271539

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training using a motion-based digital therapeutic device
Number of subjects: 363

Group type: COMPARATOR
Intervention: Home pelvic floor muscle training program using written and narrated instructions
Number of subjects: 363
Study: 34677136

Group type: EXPERIMENTAL
Intervention: Instagram ads (unlabeled ad condition)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Traditional ads (unlabeled ad condition)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Instagram ads (labeled ad condition)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Traditional ads (labeled ad condition)
Number of subjects: 832
Study: 35606882

Group type: EXPERIMENTAL
Intervention: Nano-curcumin (80 mg/day)
Number of subjects: 44
Study: 35404648

Group type: EXPERIMENTAL
Intervention: Augmented vocational rehabilitation (VR) including 12 weeks of social cognition skills training (SCST) plus 6 weeks of work-related social problem solving skills training (SPSST)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control VR group with symptom management training matched in instructional format and length to SCST and SPSST
Number of subjects: 91
Study: 33106087

Group type: EXPERIMENTAL
Intervention: Risk ladder
Number of subjects: 372

Group type: COMPARATOR
Intervention: Bulleted list
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Simplified table
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Specialized vertical bar graph (risk ladder)
Number of subjects: 372
Study: 33318632

Group type: EXPERIMENTAL
Intervention: Reverse Chromatin Immunoprecipitation (R-ChIP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcription factors (bZIP1664, TEM1, bHLH106, BTF3, HAT1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved R-ChIP method using transiently introduced DNA
Number of subjects: 0
Study: 34635802

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 32940890

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Diet adjustments
Number of subjects: 200
Study: 32980280

Group type: EXPERIMENTAL
Intervention: Pain medication (paracetamol, NSAID, opioids, neuropathic pain medication)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Neuropathic pain medication
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Pain status (no pain, nociceptive pain, neuropathic pain)
Number of subjects: 363
Study: 36003921

Group type: EXPERIMENTAL
Intervention: Lumbar transforaminal epidural block (LTEB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 100
Study: 33222502

Group type: EXPERIMENTAL
Intervention: tDCS+/rTMS-
Number of subjects: 65
Study: 32293286

Group type: EXPERIMENTAL
Intervention: Inverse Probability of Treatment Weighting (IPTW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regression adjustment
Number of subjects: 60
Study: 34813414

Group type: EXPERIMENTAL
Intervention: Prostacyclin 1 ng/kg/min infusion for 72 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 80